Over the past 5 years, the Center sustained its upward trajectory in cancer research excellence and service to its catchment area, the State of North Carolina. With Dr Sharpless?s appointment to NCI Director, in consultation with University leadership and the Center?s Scientific Advisors, Dr Earp was re-appointed UNC Lineberger Comprehensive Cancer Center (LCCC) Director for an additional term. The LCCC continued its exceptional performance of the past decade with respect to all important metrics including state service. Direct cost cancer research funding in 2019 increased to $161M of which over $54M comes from NCI; Center research space under the Director?s authority increased by ~10,000nsf; participation in interventional trials was over 11,000 accruals for the 5 year period; 36% of the more than 6,000 cancer related publication were collaborative; construction of a GMP facility was begun and a CAR T program was initiated with multiple INDs and 8 trials opened; and the Office of Community Outreach Engagement expanded LCCC?s traditional strength in community-based participatory research and implementation . The Center?s 324 members span the basic, clinical and population sciences organized into 9 programs with substantial inter- and intra-programmatic productivity. Faculty additions in the physical and pharmaceutical sciences created new opportunities in drug discovery, delivery, imaging and early detection. Substantial investment in faculty, technology and bioinformatics dramatically expanded cancer genetics research including leadership in the TCGA and expanded use of sequencing in clinical trials. LCCC population scientists initiated significant new efforts in cancer outcomes with recruitment and infrastructure for analyzing all cancer cases in our catchment area, as well as new endeavors in cancer communication, health access, survivorship and molecular epidemiology. Groundbreaking observations in breast cancer minority disparity research emerged from Center programs. Our basic programs continue to publish high-impact observations that are being translated into human therapeutics. A trans-Center Global Oncology effort received grants in each of the NCI?s new competitions. The Center?s continued expansion is driven by remarkable institutional support including direct support for cancer research from the state legislature. The UNC Lineberger requests continued funding for: 9 scientific programs; 13 shared resources; Clinical Protocol and Data Management; Protocol Review and Monitoring System, Developmental Funds, Planning, Leadership and Evaluation and Cancer Research and Career Enhancement The CCSG budget supports technological and operational expansion for a talented faculty integrated through cancer center mechanisms towards making advancements in the prevention, early detection, and treatment of cancer in North Carolina and the nation.

Public Health Relevance

The Lineberger Comprehensive Cancer Center (LCCC) forms the nexus for researchers focused on understanding and identifying the mechanisms leading to, the prevention of, and treatments for cancer. LCCC is an integral component of the research mission at The University of North Carolina (UNC) at Chapel Hill, coalescing the cancer research capabilities of the Schools of Medicine, Public Health, Pharmacy, and Nursing, and the College of Arts and Sciences. The LCCC strives to reduce cancer incidence, morbidity, and mortality in North Carolina, the United States and across the globe through innovative research, cutting-edge treatments, multi-disciplinary training, education and outreach.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Internal Medicine/Medicine
Schools of Medicine
Chapel Hill
United States
Zip Code
Shen, Hui; Shih, Juliann; Hollern, Daniel P et al. (2018) Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep 23:3392-3406
Shao, Wenwei; Chen, Xiaojing; Samulski, Richard J et al. (2018) Inhibition of antigen presentation during AAV gene therapy using virus peptides. Hum Mol Genet 27:601-613
Gao, Yanzhe; Kardos, Jordan; Yang, Yang et al. (2018) The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells. Sci Rep 8:15304
Schaefer, Kristina N; Bonello, Teresa T; Zhang, Shiping et al. (2018) Supramolecular assembly of the beta-catenin destruction complex and the effect of Wnt signaling on its localization, molecular size, and activity in vivo. PLoS Genet 14:e1007339
Zuze, Takondwa; Painschab, Matthew S; Seguin, Ryan et al. (2018) Plasmablastic lymphoma in Malawi. Infect Agent Cancer 13:22
Wang, Jeremy R; Holt, James; McMillan, Leonard et al. (2018) FMLRC: Hybrid long read error correction using an FM-index. BMC Bioinformatics 19:50
Lee, Janie M; Abraham, Linn; Lam, Diana L et al. (2018) Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography. J Clin Oncol 36:2070-2077
Thomas, Nancy E; Edmiston, Sharon N; Orlow, Irene et al. (2018) Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. J Invest Dermatol 138:2398-2404
Cousins, Emily M; Goldfarb, Dennis; Yan, Feng et al. (2018) Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3? and Activates WNT Signaling. Mol Cancer Res 16:333-344
Armstrong, Robin L; Penke, Taylor J R; Strahl, Brian D et al. (2018) Chromatin conformation and transcriptional activity are permissive regulators of DNA replication initiation in Drosophila. Genome Res 28:1688-1700

Showing the most recent 10 out of 1525 publications